RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Raises Price Target to $143
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $136 to $143.
August 02, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Neurocrine Biosciences and raises the price target from $136 to $143.
The raised price target from $136 to $143 by RBC Capital suggests a positive outlook for Neurocrine Biosciences, which could lead to a short-term increase in stock price. However, the Sector Perform rating indicates that the stock is expected to perform in line with the sector, tempering the overall impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100